In addition, we analyzed the incidence of the most common adverse events (hypertension, hand-foot syndrome, and fatigue) and their relevance to anlotinib treatment, as shown in Figs. 3 and 4, according to EGFR gene status. The gene discussed is EGFR; the disease is Hand-foot syndrome.